
CLAIMS

1. A pharmaceutical capsule for oral administration comprising a sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate salt of Formula 1 below and an enteric coating comprising an enteric polymer,
wherein the enteric polymer comprises a methacrylic acid-methyl methacrylate 1:1 copolymer and a methacrylic acid-methyl methacrylate 1:2 copolymer in a weight ratio of 1:1.

[Formula I]



2. The pharmaceutical capsule according to claim 1, characterized in that the pharmaceutical formulation comprises the enteric polymer in an amount of 10 to 300 parts by weight based on 100 parts by weight of the sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate salt.

3. The pharmaceutical capsule according to claim 1, characterized in that the pharmaceutical formulation comprises the enteric polymer in an amount of 20 to 80 parts by weight based on 100 parts by weight of the sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate.

4. The pharmaceutical capsule according to claim 1, characterized in that the pharmaceutical formulation further comprises at least one additive selected from the group consisting of microcrystalline cellulose, mannitol, hydroxypropyl methylcellulose (HPMC), polyethylene oxide, sodium croscarmellose, crospovidone, polyoxyglyceride, magnesium aluminometasilicate, magnesium stearate, talc, and sodium starch glycolate.

5. The pharmaceutical capsule according to claim 1, characterized in that the pharmaceutical formulation further comprises at least one additive selected from the group consisting of magnesium stearate, sodium starch glycolate, talc, and triethyl citrate (TEC).

6. The pharmaceutical capsule according to claim 1, characterized in that sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate is dissolved at pH 6.0 or higher.

7. The pharmaceutical capsule according to claim 1, characterized in that in the dissolution test at 37°C and 100 rpm according to the United States Pharmacopeia (USP) type 2 paddle method, 20% or less of sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate is dissolved in a pH 6.0 buffer for 1 hour, and 80% or more of sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate is dissolved in a pH 7.4 buffer for 1 hour.